We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 387

ACCC allegedly misled by Medicines Australia Code of Conduct
  • Russell Kennedy
  • Australia
  • August 25 2014

We previously reported that Medicines Australia submitted its 18th Edition of the Code of Conduct for approval by the ACCC. Subsequently, the Royal


Australian Federal Court decides protecting your brand against generic pharmaceuticals is not a misuse of market power
  • Bird & Bird
  • Australia
  • March 18 2015

In a decision which will be welcomed by many pharmaceutical companies the Federal Court of Australia recently dismissed proceedings instituted by the


ACCC imposes strict transparency provisions on updated Medicines Australia Code of Conduct
  • King & Wood Mallesons
  • Australia
  • October 28 2014

Roll-out of a new edition of Medicines Australia’s Code of Conduct has struck a roadblock, with the ACCC requesting that Medicines Australia amend


Australian antitrust enforcement focuses on healthcare & life sciences
  • Jones Day
  • Australia
  • December 22 2014

The Australian Competition and Consumer Commission (ACCC) has continued its focus on the healthcare and life sciences sectors this year, most


Sharing is caring
  • King & Wood Mallesons
  • Australia
  • June 21 2013

In its consideration of the latest in a string of authorisation applications made in the medical industry to collectively bargain on fee arrangements


ACCC v Pfizer some guidance to pharmaceutical companies on navigating competition risk
  • Herbert Smith Freehills LLP
  • Australia
  • March 3 2015

The Federal Court of Australia has recently dismissed the ACCC’s case against pharmaceutical company Pfizer. The ACCC alleged that Pfizer had misused


Pfizer case shows protecting your own position isn't anti-competitive
  • Clayton Utz
  • Australia
  • March 2 2015

Commercial strategies and practices used by Pfizer to counter the expected loss of revenue caused by the expiry of its patent over Lipitor, its


Hospital’s by-laws flatline on the competition table
  • King & Wood Mallesons
  • Australia
  • December 22 2014

The ACCC has launched proceedings in the Federal Court against Little Company of Mary Health Ltd and its subsidiary Calvary Health Care Riverina Ltd


Substantial market power now you have it, now you don’t. The decision in ACCC v Pfizer
  • Johnson Winter & Slattery
  • Australia
  • March 17 2015

The recent Federal Court decision in ACCC v Pfizer serves as strong reminder that market power is not static but must be assessed in the context of a


Harper Review - implications for the private health insurance industry
  • DLA Piper LLP
  • Australia
  • April 10 2015

On 31 March 2015 the final report of the Competition Policy Review Panel chaired by Professor Ian Harper (Harper Review) was released. The Harper